Reportable Segment — D&A
Business Segments · D&AEli Lilly Reportable Segment — D&A decreased by 1.8% to $470.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 0.7%, from $466.80M to $470.00M. Over 2 years (FY 2022 to FY 2024), Reportable Segment — D&A shows an upward trend with a 7.7% CAGR.
Analysis
StatementSegment
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2022
Last reportedQ3 2025
Rolls up toD&A
How to read this metric
High levels relative to revenue may indicate significant capital investment or heavy reliance on acquired intangible assets.
Detailed definition
Represents the systematic allocation of the cost of tangible and intangible assets over their useful lives within the re...
Peer comparison
Highly comparable across the pharmaceutical industry, particularly for firms with heavy R&D and manufacturing footprints.
Metric ID:
lly_segment_reportable_segment_depreciation_and_amortizationHistorical Data
15 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $380.63M | $380.63M | $380.63M | $380.63M | $381.83M | $381.83M | $381.83M | $381.83M | $400.60M | $414.40M | $466.80M | $484.80M | $462.80M | $478.50M | $470.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.3% | +0.0% | +0.0% | +0.0% | +4.9% | +3.4% | +12.6% | +3.9% | -4.5% | +3.4% | -1.8% |
| YoY Change | — | — | — | — | +0.3% | +0.3% | +0.3% | +0.3% | +4.9% | +8.5% | +22.3% | +27.0% | +15.5% | +15.5% | +0.7% |
Range$380.63M – $484.80M
CAGR+6.2%
Avg YoY Growth+8.7%
Median YoY Growth+4.9%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's reportable segment — d&a?
- Eli Lilly (LLY) reported reportable segment — d&a of $470.00M in Q3 2025.
- How has Eli Lilly's reportable segment — d&a changed year-over-year?
- Eli Lilly's reportable segment — d&a increased by 0.7% year-over-year, from $466.80M to $470.00M.
- What is the long-term trend for Eli Lilly's reportable segment — d&a?
- Over 2 years (2022 to 2024), Eli Lilly's reportable segment — d&a has grown at a 7.7% compound annual growth rate (CAGR), from $1.52B to $1.77B.
- What does reportable segment — d&a mean?
- The non-cash expense representing the aging of physical assets and intangible property within the segment.